Related Experiment Video
Updated: Jan 8, 2026
Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
Published on: May 21, 2018
Hypoxic Mesenchymal Stem Cell Exosome-Derived SLC25A3 Ameliorates Bronchopulmonary Dysplasia by Modulating Macrophage
Yanfang Zhang1, Aimin Zhang2, Jiale Yang1
1Pediatric Medical Center, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, China.
Insights
Hypoxia-preconditioned exosomes (Hypo-Exos) loaded with SLC25A3 show promise for treating bronchopulmonary dysplasia (BPD). These exosomes modulate macrophage polarization and reduce oxidative stress, offering a potential new therapy for BPD in preterm infants.
Area of Science:
- Biomedical research
- Cell biology
- Neonatal medicine
Background:
- Bronchopulmonary dysplasia (BPD) is a chronic lung disease in preterm infants.
- It involves macrophage dysfunction and oxidative stress.
- Mesenchymal stem cell-derived exosomes (MSC-Exos) show therapeutic potential, but the role of exosomes from hypoxia-preconditioned MSCs (Hypo-Exos) is unclear.
Purpose of the Study:
- To investigate if Hypo-Exos alleviate BPD by modulating alveolar macrophage (AM) polarization and oxidative stress.
- To explore the role of the mitochondrial transporter SLC25A3 in this process.
Main Methods:
- In vitro models of M1 macrophage polarization and oxidative stress.
- An in vivo rat model of BPD induced by intermittent hypoxia.
- Analysis of SLC25A3 packaging in exosomes and its interaction with PTEN and PI3K/AKT signaling.
Main Results:
- Hypoxic preconditioning increased exosome secretion and SLC25A3 loading into Hypo-Exos.
- Hypo-Exos suppressed M1 polarization, reduced oxidative stress, and improved lung function in BPD rats.
- SLC25A3 delivered by Hypo-Exos downregulated PTEN, activated PI3K/AKT signaling, promoted M2 polarization, and reduced oxidative damage.
Conclusions:
- Hypo-Exos containing SLC25A3 mitigate BPD progression by targeting AM polarization and oxidative stress.
- The mechanism involves the SLC25A3-PTEN-PI3K/AKT pathway.
- Hypo-Exos represent a potential therapeutic strategy for BPD.
Abstract:
Bronchopulmonary dysplasia (BPD) is a prevalent chronic lung disease in preterm infants, characterized by dysregulated macrophage polarization and oxidative stress. While mesenchymal stem cell-derived exosomes (MSC-Exos) have shown protective effects against BPD, the role of exosomes derived from hypoxia-preconditioned MSCs (Hypo-Exos) remains unclear. This study aimed to investigate whether Hypo-Exos alleviate BPD by modulating alveolar macrophage (AM) polarization and oxidative stress via the mitochondrial transporter SLC25A3. We utilized in vitro models of LPS-induced M1 polarization and H2O2-induced oxidative stress in AMs, as well as an in vivo rat model of BPD induced by intermittent hypoxia. Our data demonstrate that hypoxic preconditioning enhanced exosome secretion from MSCs. Furthermore, hypoxic preconditioning promoted the packaging of SLC25A3 into these exosomes. Hypo-Exos significantly suppressed M1 polarization, reduced oxidative stress, and ameliorated lung injury and dysfunction in BPD rats. Silencing SLC25A3 in MSCs abolished these protective effects. Mechanistically, SLC25A3 interacted with PTEN, leading to inhibition of PTEN expression and activation of the PI3K/AKT signaling pathway. Overexpression of PTEN reversed the beneficial effects of SLC25A3 on macrophage polarization and oxidative stress. These findings reveal that Hypo-Exos deliver SLC25A3 to AMs, thereby downregulating PTEN, activating PI3K/AKT signaling, promoting M2 polarization, attenuating oxidative damage, and ultimately mitigating BPD progression. This study provides important mechanistic insights and suggests potential therapeutic avenues for exosome-based treatment of BPD.
